Your browser doesn't support javascript.
loading
Circulating suPAR associates with severity and in-hospital progression of COVID-19.
Chalkias, Athanasios; Skoulakis, Anargyros; Papagiannakis, Nikolaos; Laou, Eleni; Tourlakopoulos, Konstantinos; Pagonis, Athanasios; Michou, Anastasia; Ntalarizou, Nicoletta; Mermiri, Maria; Ragias, Dimitrios; Bernal-Morell, Enrique; Cebreiros López, Iria; García de Guadiana-Romualdo, Luis; Eugen-Olsen, Jesper; Gourgoulianis, Konstantinos; Pantazopoulos, Ioannis.
Afiliación
  • Chalkias A; Department of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
  • Skoulakis A; Outcomes Research Consortium, Cleveland, Ohio, USA.
  • Papagiannakis N; Department of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
  • Laou E; First Department of Neurology, Medical School, Aiginition University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Tourlakopoulos K; Department of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
  • Pagonis A; Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, Larisa, Greece.
  • Michou A; Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, Larisa, Greece.
  • Ntalarizou N; Department of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
  • Mermiri M; Department of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
  • Ragias D; Department of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
  • Bernal-Morell E; Department of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
  • Cebreiros López I; Infectious Diseases Unit, Department of Internal Medicine, Hospital General Universitario Reina Sofía, Murcia, Spain.
  • García de Guadiana-Romualdo L; Department of Laboratory Medicine, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Eugen-Olsen J; Department of Laboratory Medicine, Hospital General Universitario Santa Lucía, Cartagena, Spain.
  • Gourgoulianis K; Department of Clinical Research, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
  • Pantazopoulos I; Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, Larisa, Greece.
Eur J Clin Invest ; 52(7): e13794, 2022 Jul.
Article en En | MEDLINE | ID: mdl-35435245
BACKGROUND: COVID-19 disease progression is characterized by hyperinflammation and risk stratification may aid in early aggressive treatment and advanced planning. The aim of this study was to assess whether suPAR and other markers measured at hospital admission can predict the severity of COVID-19. METHODS: The primary outcome measure in this international, multi-centre, prospective, observational study with adult patients hospitalized primarily for COVID-19 was the association of WHO Clinical Progression Scale (WHO-CPS) with suPAR, ferritin, CRP, albumin, LDH, eGFR, age, procalcitonin, and interleukin-6. Admission plasma suPAR levels were determined using the suPARnostic® ELISA and suPARnostic® Turbilatex assays. RESULTS: Seven hundred and sixty-seven patients, 440 (57.4%) males and 327 (42.6%) females, were included with a median age of 64 years. Log-suPAR levels significantly correlated with WHO-CPS score, with each doubling of suPAR increasing the score by one point (p < .001). All the other markers were also correlated with WHO-CPS score. Admission suPAR levels were significantly lower in survivors (7.10 vs. 9.63, 95% CI 1.47-3.59, p < .001). A linear model (SALGA) including suPAR, serum albumin, serum lactate dehydrogenase, eGFR, and age can best estimate the WHO-CPS score and survival. Combining all five parameters in the SALGA model can improve the accuracy of discrimination with an AUC of 0.80 (95% CI: 0.759-0.836). CONCLUSIONS: suPAR levels significantly correlated with WHO-CPS score, with each doubling of suPAR increasing the score by one point. The SALGA model may serve as a quick tool for predicting disease severity and survival at admission.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores del Activador de Plasminógeno Tipo Uroquinasa / COVID-19 Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Clin Invest Año: 2022 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores del Activador de Plasminógeno Tipo Uroquinasa / COVID-19 Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Clin Invest Año: 2022 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Reino Unido